Cracking the code on post-vaccine COVID protection
The study investigates the relationship between antibody levels and behavioral factors in 176 adults vaccinated with Pfizer's BNT162b2, finding that higher levels of specific antibodies correlate with greater protection against symptomatic COVID-19. It also suggests that current commercial assays may need reformatting for better risk prediction.
Source: news-medical.net